Sector News

Santen establishes UK subsidiary

November 5, 2014
Life sciences
Japanese drugmaker Santen has set up shop in the UK to help push its recently acquired glaucoma franchise from Merck & Co into the market.
 
The group said it has established a UK subsidiary to promote products such as Saflutan and Cosopt – purchased from Merck back in May for $600 million plus royalties – and help strengthen its footprint in Europe.
 
“The establishment of our own subsidiary in the UK is an important step in achieving our long term corporate vision to become a specialised pharmaceutical company with a global presence”, said Masamichi Sato, Head of Santen European Group and President of Santen Holding EU BV.
 
The move will allow the group to provide its complete portfolio of products throughout Europe, and the launch of commercial teams in other European countries such as Spain, Portugal or Benelux “is expected within the next few months,” he added.
 
By Selina McKee
 
Source: Pharma Times
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach